February 2026 Research Update

This month added several early, preclinical signals that targeting specific brain pathways can improve Rett-like features in mouse models, but these results are not yet proof of benefit for people. Across different approaches, the shared pattern was improvement in measurable outcomes such as breathing pauses, seizure-like brain activity, and behavior, suggesting multiple biological routes might be worth testing further. The studies also repeatedly tied symptom changes to changes in inflammation or synapse-related markers, which helps explain how these approaches might work in the lab. [1] [2] [3]

One approach focused on immune cells in the brain called microglia, using D-TTM020 (a dendrimer-conjugated glutaminase inhibitor) to reduce microglial glutaminase activity. In two Rett mouse models, this was linked to better composite behavior measures, improved fear-learning tasks, increases in synapse-related proteins (like BDNF and PSD-95), and lower levels of inflammatory signals (IL-1beta and TNF-alpha) compared with saline or the free (non-targeted) drug. This points to microglial metabolism and inflammation as a potentially important lever in Rett-like symptoms, at least in mice. [1]

Another approach aimed to strengthen inhibitory signaling by activating KCC2 (a transporter that helps neurons keep chloride levels in balance), using a compound called OV350. In female MeCP2+/- mice, OV350 was reported to reduce EEG power and epileptic discharges and to improve motor coordination, sociability, and spatial memory, alongside correction of a KCC2 phosphorylation problem seen in these mice. This supports the idea that inhibitory signaling problems may contribute to brain rhythm and behavior changes in Rett models. [2]

A third line of work connected a specific brain receptor, mGlu7, to Rett biology and breathing-related outcomes in a mouse model. In human Rett brain samples, mGlu7 mRNA levels were reported to be lower, especially in people with severe MECP2 mutations, while related receptors (mGlu4 and mGlu8) were not decreased. In mice with a MeCP2 mutation (R306C), an mGlu7-positive allosteric modulator called VU0422288 reduced apneas, giving an early, model-based hint that this pathway could matter for breathing symptoms. [3]

For families, the main message is that several different lab-based strategies showed symptom improvements in Rett mouse models, which helps researchers prioritize what to study next. These findings may matter later if they hold up in more testing and eventually in human studies, but they do not tell us yet what will work for an individual person with Rett syndrome. What remains uncertain includes how well these mouse outcomes translate to daily-life symptoms in people, and which subgroups (by age, sex, or MECP2 variant) would be most likely to benefit if these approaches move forward. [1] [2] [3]

This month strengthened a picture of Rett syndrome as a condition where brain and body systems can look "active" on the surface but be less stable or less well-balanced underneath. In mouse brain imaging during learning, neurons formed place-related activity patterns but those patterns were less stable over days, which matches the idea of difficulties with memory consolidation. Other studies pointed to specific molecular competition and cell-to-cell signaling problems that could help explain why changes show up across many organs, including blood vessel barriers and bone. [4] [5] [6] [7] [8] [9]

In a multi-day learning task, female Mecp2+/- mice had more active place cells and more plasticity events, but their hippocampal activity patterns were less consistent from day to day and position decoding was less accurate. In plain language, the study suggests the brain may still be trying to learn, but the learning-related changes may be "mis-aimed" and harder to keep stable over time, which could contribute to memory problems. The authors also used a computational model to show that increased spontaneous activity and misdirected plasticity could recreate the instability seen in the mice. [4]

At the molecular level, one study clarified how MeCP2 can bind both DNA and RNA using a combined MBD-ID interface, and that RNA binding can block DNA binding. Rett-associated mutations in the intervening domain (ID) were reported to weaken RNA and non-methylated DNA binding without changing methylated DNA binding, which could upset how MeCP2 balances different nucleic acid interactions. This gives a more specific explanation for how some MECP2 mutations might cause problems even if one type of binding appears preserved. [5]

Several studies highlighted that MECP2 changes can affect non-neuronal cells in ways that could matter for whole-body symptoms. In patient-derived iPSC microvascular networks, Rett-derived networks were more permeable than matched controls, and this hyperpermeability was linked to higher miR126-3p and could be rescued by restoring miR126-3p levels. Separately, in human osteoblasts with MECP2 knockdown, bone-forming programs were reduced with higher DKK1 and lower Wnt signaling, and blocking miR-126-3p partially restored bone-related markers and mineralization. [6] [7]

Cell-to-cell signaling also remained a focus, with evidence that Rett astrocytes can send out signals that reduce excitatory synapse formation in otherwise typical neurons. In an indirect co-culture system, treating Rett astrocytes with the IGF1-derived peptide IGF1(1-3) reversed this synapse effect and was linked to lower levels of IGFBP2 (a protein that can bind IGF1), improved mitochondrial function, and stronger PI3K/Akt signaling in neurons. This supports the idea that some Rett-related brain changes may come from altered support-cell signals rather than neuron problems alone. [9]

Another mouse study focused on how chromatin-associated proteins change with age and brain region, including MeCP2 and histone H1. In typical mice, H1 and MeCP2 increased in the cerebellum from P21 to P56 while histone H3 stayed largely stable, and this pattern was not the same in the cerebral hemisphere. In Mecp2 T158M mutant mice, Purkinje cells had higher H1 alongside lower MeCP2 protein and higher Mecp2 transcripts, consistent with a mismatch between gene message and protein level in this model. [8]

For patients and caregivers, these studies mostly add understanding of why Rett can affect many functions at once, and why symptoms like learning difficulties can be hard to predict day to day. The work on brain learning stability, MeCP2 DNA/RNA binding, blood-vessel barrier properties, and bone-forming cells is mainly early research, but it helps map out specific processes that future therapies might try to correct. What remains uncertain is how directly these lab findings connect to specific symptoms in an individual person, and which of these pathways will matter most when tested in human studies. [4] [5] [6] [7] [8] [9]

This month, the human studies mainly helped clarify what symptoms and trajectories can look like over time, and they offered one small early signal in difficult-to-treat seizures. Observational work in school-aged girls showed a gradual decline in gross motor skills, with scoliosis severity and acute events contributing to worse movement scores. A separate caregiver survey study highlighted how common sleep problems, epilepsy, and gastrointestinal symptoms are, and how sleep quality related to family well-being. [10] [11] [12]

In a Danish cohort of 33 girls followed over time, gross motor skills measured from video tended to decline gradually, with the largest declines in standing and walking abilities. The analysis also reported that more severe scoliosis and acute events like seizures or fractures contributed to declines, while surgically corrected scoliosis showed smaller declines. This helps set expectations for how movement may change during school age and shows that trajectories can differ with comorbidities. The study also found differences in average motor scores between some MECP2 variants, but it was too small to determine whether the rate of change over time differed by variant. [10]

In a cross-sectional study of 77 Turkish children with Rett syndrome, epilepsy and gastrointestinal symptoms were common, and many children had limited speech and independent walking. Sleep problems were reported in nearly half of children, with parasomnia symptoms more common in the youngest age group, and poorer sleep linked to worse family relations. This adds a clearer picture of how symptom burden and quality of life can vary by age, especially around sleep and emotional functioning. [11]

A small multicenter case series described fenfluramine use in 4 children with MECP2-related Rett syndrome and drug-resistant epilepsy. Three children had substantial seizure reductions and one did not improve, and mild side effects were reported in one child and resolved after a temporary stop, with no cardiac adverse events reported in this series. This is an early clinical signal, but the small number of patients means it cannot tell how often this response happens across the broader Rett community. [12]

For families, these studies may matter now mainly by improving understanding of common challenges in Rett syndrome, such as movement changes over time and the impact of sleep on family well-being. The fenfluramine report may matter later if confirmed in larger groups, because it suggests some children with hard-to-control seizures may see improvement, but it is not strong enough evidence to predict what will happen for any one child. What remains uncertain includes how motor trajectories vary in larger populations and which seizure treatments help which subgroups, since the human treatment evidence this month was based on only 4 patients. [10] [11] [12]

The case reports this month expanded the range of possible Rett-related presentations, especially at very young ages and with prominent gastrointestinal symptoms. A separate data paper released a large protein dataset from MECP2-mutant and control brain organoids, which is not a clinical finding but could support future studies. Together, these items mostly add awareness and research infrastructure rather than changing what is known about typical Rett syndrome. [13] [14] [15]

One report described a female newborn with neonatal encephalopathy who had exome sequencing showing an MECP2 variant classified as a variant of uncertain significance. The authors raised the possibility that MECP2-related neonatal encephalopathy can occur in females, but the genetic result was not definitive because the variant was not confirmed as disease-causing and parental testing was not available. This case mainly highlights diagnostic uncertainty that can happen when a gene change is found early in life. [13]

Another report described a 3-year-old boy with intestinal pseudo-obstruction who was found to have a pathogenic MECP2 variant, described as an atypical Rett presentation. The child had major feeding and growth challenges that improved with enteral nutrition support and other management, and neurological findings were described as mild. This case emphasizes that gastrointestinal symptoms can be a prominent part of MECP2-related disorders in some children. [14]

The data paper provided a proteomics dataset from iPSC-derived human brain organoids with an MECP2 mutation and a matched control, including samples grown on Earth and during spaceflight. It reported deep protein coverage of about 6,000 protein groups, offering a resource that other researchers can use to explore MECP2-related neurobiology under different conditions. This is a research tool rather than evidence about symptoms or treatments. [15]

For patients and caregivers, case reports can be useful for showing what is possible, but they cannot estimate how common a presentation is. The newborn case underscores that an MECP2 change can sometimes be found early, but a variant of uncertain significance does not provide clear answers by itself. The gastrointestinal case may help families recognize that feeding and motility problems can be part of some MECP2-related conditions, while the organoid dataset is mainly future-facing research that could support new discoveries later. [13] [14] [15]